Half Year 2025 Sandoz Group AG Earnings Call Transcript
Key Points
- Sandoz Group AG (SDZNY) reported a 4% sales growth in H1 2025, with an underlying growth of 6%, driven by accelerated sales in the second quarter.
- The company's core EBITDA margin expanded by 2.5 percentage points to 20%, reflecting an improved sales mix and operational efficiency.
- Successful execution of biosimilar launches, including Pyzchiva in the US and Europe, and Wyost and Jubbonti in the US, strengthens Sandoz's portfolio.
- Expansion of manufacturing capabilities in Slovenia and the planned acquisition of Just-Evotec Biologics in France are set to enhance Sandoz's biosimilar platform.
- Sandoz maintains a strong financial position with a significant improvement in cash generation, doubling management cash flow to over $500 million.
- Price erosion remains a challenge, impacting the core gross profit margin, which declined by around 1 percentage point.
- The US biosimilars market performance was softer than expected, with a need for stronger growth in the second half of the year.
- Separation costs from the former parent company are expected to reach around $500 million for the full year, impacting financials.
- The competitive landscape in the US, particularly for products like Hyrimoz, presents pricing pressures and challenges in maintaining market share.
- The impact of potential US tariffs on EU imports could affect financial performance, with an anticipated impact of $25 million in 2025 and $70 million in 2026.
Good morning ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations for his opening remarks.
Thank you, and welcome to the Sandoz H1 2025 results call. Earlier today, we published our results announcement and an accompanied presentation on our website, which we'll follow today. You can find these documents at sandoz.com/investors. Joining me on today's call are Richard Saynor, Chief Executive Officer; and Remco Steenbergen, Chief Financial Officer. Please turn to slide 2.
Our results announcement presentation and discussion include forward-looking statements. Please see our disclaimer here.
Please turn to slide 3. Richard will begin today's presentation with a summary of the highlights in the first half of the year, followed by an update on the business. Remco will cover the financial performance as well as our full year guidance. Following a wrap-up of the presentation, we'll be happy to take your questions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
